Floatz Rating
D29/100
Confidence
Indicative
Sponsor
Takeda
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
17High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05976334CT.gov An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT03648372CT.gov A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sumoylation Inhibitor Tak-981 (this asset) | Takeda | P1/2 | D · 29 |
| Panitumumab | Astellas Pharma Inc | P2 | BB |
| Irinotecan | Mirati Therapeutics Inc. | P4 | BB |
| Nivestim | Ankara Etlik City Hospital | P2 | BB |
| Dexasone | Hellenic Society of Hematology | P3 | BB |
| Feladilimab | GlaxoSmithKline | P2 | BB |
| Pralsetinib, Trans- | Seoul National University Bundang Hospital | P3 | BB |
| Carboplatin | Bristol-Myers Squibb | P3 | BB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Sumoylation Inhibitor Tak-981
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P1/2 | D · 28 |
| Hematopoietic And Lymphoid System Neoplasm | — | P1/2 | D · 28 |
| Non-Hodgkin Lymphoma | — | P1/2 | D · 28 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sumoylation Inhibitor Tak-981 in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/sumoylation-inhibitor-tak-981-neoplasm-111882
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →